Results 41 to 50 of about 6,174 (184)

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

BMC Cancer, 2023
Background The optimal treatment strategy for resectable BRAF V600E mutant colorectal oligometastases (CRM) has not been established due to the rarity and rapid progression of the disease.
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, Takeshi Takamoto, Eiji Shinozaki, Manabu Shiozawa, Hiroki Hara, Kentaro Yamazaki, Koji Komori, Nobuhisa Matsuhashi, Takeshi Kato, Yoshinori Kagawa, Mitsuru Yokota, Eiji Oki, Keigo Komine, Shinichiro Takahashi, Masashi Wakabayashi, Takayuki Yoshino   +17 more
doaj   +1 more source

Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. [PDF]

, 2016
BackgroundUBE4B is an E3/E4 ubiquitin ligase whose gene is located in chromosome 1p36.22. We analyzed the associations of UBE4B gene and protein expression with neuroblastoma patient outcomes and with tumor prognostic features and histology.MethodsWe ...
Bean, Andrew J, Guo, Rong Jun, Hollingsworth, Emporia Faith, Indiviglio, Sandra, Ittmann, Michael, Liu, Yin, Lopez-Terrada, Dolores, Major, Angela M, Mo, Qianxing, Whittle, Sarah B, Woodfield, Sarah E, Zage, Peter E   +11 more
core   +2 more sources

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib

Case Reports in Oncological Medicine, 2019
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver
Nicholas Gravbrot, Srinath Sundararajan
doaj   +1 more source

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database

Frontiers in Pharmacology
ObjectiveTo investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).MethodsReports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004–2023q3) were ...
Shuang Xia, Shuang Xia, Shuang Xia, Jing-Wen Xu, Kang-Xin Yan, Yoshihiro Noguchi, Mayur Sarangdhar, Mayur Sarangdhar, Mayur Sarangdhar, Miao Yan, Miao Yan, Miao Yan   +11 more
doaj   +1 more source

Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations

Pharmaceutics, 2023
Tyrosine kinase inhibitors (TKIs) are used as targeted cancer therapies in adults and have an off-label pediatric application for the treatment of Langerhans cell histiocytosis.
Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi   +9 more
doaj   +1 more source

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. [PDF]

, 2019
Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency ...
Li, Hui, Liu, Hong, Liu, Jing, Liu, Juan, Liu-Smith, Feng, Roy, Mridul, Sun, Shuming, Wang, Zi, Xiao, Xiaojuan, Ye, Mao, Zhang, Bin, Zhang, Hui, Zhang, Yibin, Zhou, Weihua   +13 more
core   +1 more source

Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature

Current Problems in Cancer: Case Reports, 2021
Encorafenib/binimetinib combination is approved for BRAF mutated melanoma and is being increasing used. The landmark COLUMBUS trial reports
Nabin Raj Karki, Himax Patel, Luvika Gupta, Nagla Abdel Karim   +3 more
doaj   +1 more source

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer [PDF]

, 2023
RAS mutation; Binimetinib; Colorectal cancerMutació RAS; Binimetinib; Càncer colorectalMutación RAS; Binimetinib; Cáncer colorrectalIntroduction Activating RAS gene mutations occur in approximately 55% of patients with metastatic colorectal cancer (mCRC)
DELORD, Jean-Pierre, Ducreux, Michel, Elez, Elena, Siu, Lillian, Tabernero, Josep, Van Cutsem, Eric, Yaeger, Rona   +6 more
core   +1 more source

THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES

Сибирский онкологический журнал, 2019
Introduction. Cutaneous melanoma is a challenge to treat due to rapid progression of disease and acquired resistance to therapy. Autophagy and the epithelial-to-mesenchymal transition (EMT) are closely interrelated and play a key role in tumor ...
A. S. Lozhkomoev, O. V. Bakina, A. N. Fomenko, A. V. Avgustinovich, S. G. Afanasyev, A. Yu. Dobrodeev, L. V. Spirina, A. S. Tarasova, U. B. Urmonov   +8 more
doaj   +3 more sources

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab

CNS Oncology
This report describes a case of BRAF V600E-mutated colorectal cancer with CNS metastases in which treatment with encorafenib, binimetinib and cetuximab was effective.
Toru Imai, Hirokazu Shoji, Hidekazu Hirano, Kunihito Matsuguma, Takahito Awatsu, Toshiharu Hirose, Natsuko Okita, Atsuo Takashima, Ken Kato   +8 more
doaj   +1 more source